Merck Serono recently launched a spin-off, Quartz Bio, which will provide biomarker data management and analysis services for pharmaceutical companies. Quartz Bio meets the developing needs of pharmaceutical companies, both in the drug development pipeline and once the drug is on the shelf. Biomarker analyses can help pharmaceutical companies design better clinical trials, because they can be used to predict which patients will respond to which therapies, potentially helping doctors tailor treatments to individual patients. This article emphasizes the enormous clinical importance of biomarkers, a major focus of Prize4Life’s programmatic initiatives.
Click here to read more.Share this: